Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000694591 | SCV000823042 | benign | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001312075 | SCV001502515 | uncertain significance | not provided | 2020-10-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001312075 | SCV003833403 | likely benign | not provided | 2023-12-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003338735 | SCV004057735 | uncertain significance | Inborn genetic diseases | 2023-08-04 | criteria provided, single submitter | clinical testing | The c.3782G>A (p.S1261N) alteration is located in exon 19 (coding exon 18) of the COL12A1 gene. This alteration results from a G to A substitution at nucleotide position 3782, causing the serine (S) at amino acid position 1261 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV001312075 | SCV004223889 | uncertain significance | not provided | 2022-03-25 | criteria provided, single submitter | clinical testing |